Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

Moti Ramgopal, Antonella Castagna, Charles Cazanave, Vicens Díaz-Brito, Robin Dretler, Shinichi Oka, Olayemi Osiyemi, Sharon Walmsley, James J. Sims, Giovanni Di Perri, Kenneth Sutton, Denise Sutherland‐Phillips, Alessandro Berni, Christine L. Latham, Feifan Zhang, Ronald D’Amico, Miguel Pascual Bernáldez, Rodica Van Solingen‐Ristea, Veerle Van Eygen, Parul Patel, Vasiliki Chounta, William Spreen, H Garges, Kimberly Y. Smith, Jean van Wyk